CIK 0001534120 · Non-accelerated filer<br>Smaller reporting company
Avalo Therapeutics, Inc.
Sign in to watch- Ticker
- AVTX
- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- operating
- EIN
- 450705648
- Phone
- 410-522-8707
- Business address
- 1500 LIBERTY RIDGE DRIVE, SUITE 321, WAYNE, PA, 19087
- Former names
- Cerecor Inc.
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $1,865,893
- in 5 filings, $1.9M under 10b5-1 plans
Net −$1,865,893. Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Who's trading
90 days
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −9,219 | $21.37 | $197K | 9,323 |
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −8,900 | $22.57 | $201K | 423 |
| 2026-05-06 | Sullivan Christopher Ryan Chief Financial Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −47,000 | 116,000 | ||
| 2026-05-06 | Chan Mitchell Director | Sale 10b5-1 | −3,167 | $22.88 | $72K | 3,166 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Option exercise 10b5-1 | +62,500 | $13.43 | $839K | 66,134 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Option exercise 10b5-1 | +12,563 | $8.04 | $101K | 78,697 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Sale 10b5-1 | −37,375 | $18.91 | $707K | 41,322 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Sale 10b5-1 | −5,196 | $19.78 | $103K | 36,126 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Sale 10b5-1 | −22,839 | $21.22 | $485K | 13,287 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Sale 10b5-1 | −9,253 | $22.70 | $210K | 4,034 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Sale 10b5-1 | −400 | $23.71 | $9K | 3,634 |
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −62,500 | 87,500 | ||
| 2026-05-06 | VARKI PAUL Chief Legal Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −12,563 | 87,437 | ||
| 2026-05-05 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +1,000 | $12.65 | $13K | 4,622 |
| 2026-05-05 | Doyle Mittie Chief Medical Officer | Option exercise 10b5-1 | +679 | $8.04 | $5K | 5,301 |
| 2026-05-05 | Doyle Mittie Chief Medical Officer | Sale 10b5-1 | −1,679 | $16.00 | $27K | 3,622 |
| 2026-05-05 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −1,000 | 209,530 | ||
| 2026-05-05 | Doyle Mittie Chief Medical Officer | Option exercise · Stock Option (Right to Buy) 10b5-1 | −679 | 147,650 | ||
| 2026-04-30 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −8,457 | $13.23 | $112K | 423 |
| 2026-04-29 | Sullivan Christopher Ryan Chief Financial Officer | Sale 10b5-1 | −8,458 | $13.09 | $111K | 8,880 |
Page 5 of 11 · 202 trades